Better Target Validation for Drug Discovery with CRISPR/Cas9
October 23, 2018 - Toronto ON CAXtalks
fbonilla@xtalks.com
Phone:4169776555
Better target validation is a key driver of better productivity in drug discovery. The RNA-guided nucleases, exemplified by Cas9, represent a powerful new approach to understanding gene function and, in principle, to reveal the next generation of therapeutic targets. But how well does this technology work in practice?
This website uses cookies to ensure you get the best experience on our website. Learn more